الفهرس | Only 14 pages are availabe for public view |
Abstract Background: Hodgkin’s lymphoma (HL) is a highly curable malignant disease. Risk-adapted therapy for children with HL is directed toward high survival, minimal toxicity and optimal quality of life. 18F-FDG PET is a well-established surrogate for tumor chemosensitivity early during therapy. The ongoing PET-adaptive clinical trials are testing the hypothesis that a decision can reliably be made on escalating or deescalating therapy based on interim PET results. Aims: In this study we aimed to identify the prognostic role of interim PET in predicting the prognosis of HL in our center. Methods: This is a retrospective, single center study where a total of 140 patients with newly diagnosed Hodgkin lymphoma were enrolled. Only 83 patients were eligible for analysis of interim PET. PET scan was performed at baseline and after two cycles of chemotherapy. Treatment was not changed according to the results of the interim scan. PET scans reports was used using the Deauville five-point scale, blinded to treatment outcome |